BiondVax Pharmaceuticals announced the appointment of Mark Germain as Vice-Chairman of its Board of Directors.
Based in New York, and having served as founder, director, chairman of the board, and/or investor in over twenty biotech companies, and with experience assisting in arranging corporate partnerships, acquiring technology, entering mergers and acquisitions, and executing financings, Germain will help guide BiondVax's ongoing corporate development. Among his current positions, Germain is a Managing Director at The Aentib Group, a boutique merchant bank, and serves as a director on the board of the Israeli company Pluristem Therapeutics.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"I am pleased and excited to join the BiondVax board at this important time in the development of the company. It is about to commence a Phase 3 pivotal trial for its universal flu vaccine, an innovative multi-strain, multi-season product with the potential to protect against pandemic strains as well. We have a strong shareholder base, with €20 million additional non-dilutive funding from the European Investment Bank, and are poised to build a successful company,” Germain said. “I'm looking forward to working with our CEO Ron Babecoff, the rest of the board, and shareholders."
"On behalf of BiondVax's Board of Directors, I warmly welcome Mark's appointment. I am confident that his biotech and corporate experience and track record will contribute significantly to BiondVax's upcoming activities," Dr. Ron Babecoff, BiondVax's President and CEO, said.